b.

baseimmune.

®

TM

designing vaccines with plasticity

About Us

baseimmune is a biotech startup founded to create the next generation of vaccines. Our unique platform is based on innovative and powerful technology which is able to generate antigens using a level of informatics depth not previously seen. 


Using this approach we are able to tackle emerging and challenging pathogens that had been failed by traditional approaches and importantly able to ensure our vaccines remain effective even if a pathogen mutates.


As a discovery phase biotech, we offer our antigen discovery services and develop broad-spectrum vaccines against highly variable pathogens. 

b.

Technology

Predict the Future

Pathogens are evolving constantly to adapt and ensure their survival. As a result they are a constantly moving target for vaccines.  Some vaccines may work for a short period, whilsts others may never be able to keep up with a pathogens variation. Baseimmune uses deep learning to predict the direction that a pathogen will take to create vaccines that are many steps ahead and future proof. Introducing Baseimmune vaccines with plasticity.

TM

To Create Vaccines with Plasticity

TM

Our technologies are based on a data-driven platform for the analysis of pathogen genomics, proteomics, epidemiology, evolution and clinical data for the generation of vaccine antigens effective against current and future unknown strains and variants.

Team

Co-founder, CEO

Co-founder, CSO

Co-founder, CTO

Danny

Goovaerts

Michael

Watson

Prof. Jake

Baum

Veterinary Commercialisation

Commercial Advisor

Scientific Advisor

With talented vaccine experts, scientists, bioinformaticians and software engineer in the field, baseimmune is committed to translating ‘OMICs’ big-data into real-world solutions. By collaborating with leading institutions and companies and an expert panel of scientific advisors, we hope to develop  vaccines and reduce the burden of infectious diseases in human and animal health.

Pipeline

The baseimmune pipeline currently focuses on major challenges in infectious diseases. We are building a unique pipeline to address veterinary and human threats worldwide.  

DESIGN

PRECLINICAL

PHASE I

BSIvet-001 vaccine 

BSIvet-002 vaccine

BSIhum-002 vaccine

BSIhum-003 vaccine

Universal African Swine Fever

Universal Porcine Repro. & Resp Syndrome

Universal Coronavirus

Universal Malaria

Our bespoke antigen discovery platform allied with superior vaccine delivery systems, allow us to fast track the discovery phase of vaccines and move faster to preclinical pipeline. 

baseimmune joins cohort 2 of the KQLabs accelerator program held at the Crick Institute

baseimmune features in UKSpine article about startups from academics

News

Co-development of a malaria vaccine

baseimmune is combining forces with Imperial College to develop a radically new malaria vaccine

b.

Who are we?

meet the baseimmune team and find out what we do

n

Baseimmune Raises investment

Baseimmune team raises funds to create future-proof vaccines

n

Career Opportunities

Join the team to harness the power of our computational platform to design and create variant-proof vaccines. We’re currently recruiting for a vaccinologist to working with our rapidly expanding team.

Vaccinologist

Posted: 31st Aug 2021        Closing: 23rd Sept 2021

Further Vaccancies

Check back soon

Working with world-class

research institutes

Funders

We are funded and supported by the Creator Fund, Maki.vc, Rockmount Seed Investments, Tiny.vc, Voyagers, Angels and the KQ labs accelerator. 

Contact

If you’d like to know more, contact us.

baseimmune

®

© 2021 baseimmune. All rights reserved

Sir Alexander Fleming Building, Imperial College London, London, SW7 2AZ